Table 2. Stratification analysis for association between H19 genotypes and neuroblastoma susceptibility.

Variables	rs2839698 (patient/control)		Adjusted OR1	P1	rs3024270 (patient/control)		Adjusted OR1	P1	rs217727 (patient/control)		Adjusted OR1	P1	Risk genotypes (patient/control)		Adjusted OR1	P1
	GG/AG	AA	(95% CI)		CC/CG	GG	(95% CI)		GG/AG	AA	(95% CI)		0	1-3	(95% CI)
Age, months
≤18	110/276	15/29	1.29 (0.66–2.50)	0.452	95/240	31/65	1.21 (0.74–1.97)	0.454	116/270	10/35	0.67 (0.32–1.39)	0.278	85/205	41/100	0.99 (0.64–1.54)	0.962
>18	243/462	24/43	1.06 (0.63–1.79)	0.830	207/397	60/108	1.07 (0.75–1.52)	0.727	234/454	33/51	1.25 (0.79–2.00)	0.342	173/346	94/159	1.18 (0.86–1.62)	0.297
Sex
Female	148/317	20/24	1.79 (0.96–3.34)	0.068	123/278	45/63	1.61 (1.04–2.50)	0.032	152/302	16/39	0.83 (0.45–1.53)	0.546	107/239	61/102	1.35 (0.91–1.99)	0.137
Male	206/421	19/48	0.83 (0.48–1.45)	0.516	179/359	46/110	0.85 (0.57–1.25)	0.398	198/422	27/47	1.22 (0.74–2.02)	0.442	151/312	74/157	0.98 (0.70–1.37)	0.899
Sites of origin
Adrenal gland	140/738	13/72	0.97 (0.52–1.80)	0.915	115/637	38/173	1.23 (0.82–1.84)	0.327	133/724	20/86	1.24 (0.73–2.08)	0.430	94/551	59/259	1.33 (0.93–1.90)	0.122
Retroperitoneal	79/738	8/72	1.01 (0.47–2.18)	0.982	67/637	20/173	1.08 (0.64–1.83)	0.776	82/724	5/86	0.52 (0.21–1.32)	0.169	62/551	25/259	0.85 (0.52–1.39)	0.516
Mediastinum	98/738	11/72	1.16 (0.59–2.27)	0.661	89/637	20/173	0.84 (0.50–1.40)	0.493	95/724	14/86	1.25 (0.68–2.28)	0.478	75/551	34/259	0.97 (0.63–1.50)	0.901
Others	30/738	6/72	2.00 (0.81–4.99)	0.135	24/637	12/173	1.82 (0.89–3.73)	0.100	34/724	2/86	0.50 (0.12–2.13)	0.350	22/551	14/259	1.35 (0.68–2.69)	0.391
Clinical stage
I+II+4s	146/738	16/72	1.13 (0.64–2.00)	0.677	126/637	36/173	1.06 (0.70–1.59)	0.792	143/724	19/86	1.13 (0.66–1.91)	0.661	107/551	55/259	1.10 (0.77–1.57)	0.602
III+IV	190/738	21/72	1.17 (0.70–1.95)	0.561	160/637	51/173	1.19 (0.83–1.71)	0.335	187/724	24/86	1.06 (0.65–1.71)	0.821	135/551	76/259	1.20 (0.87–1.65)	0.259

¹Adjusted for age and sex.

Values in bold inidicate P<0.05.